You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
WALTHAM, Mass. , March 01, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Company management will be attending and participating in the 2019 Credit Suisse Global Healthcare Conference in London on Tuesday, March 5, 2019 and hosting one-on-one meetings with
TYMLOS® U.S. net sales continued to increase, reaching $34.4 million in the fourth quarter of 2018 and totaling $99.2 million for full-year 2018, exceeding the Company’s guidance of $95-98 million . Elacestrant’s Phase 3 study was initiated at the end of 2018 and is open for enrollment.
WALTHAM, Mass. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Leerink Partners 8 th Annual Global Healthcare Conference on Friday, March 1, 2019 .
WALTHAM, Mass. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019 . The Company will host a conference call and live audio webcast at 4:30 p.m.
WALTHAM, Mass. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and
WALTHAM, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales surpassing the upper range of $95 to $98 million . Radius closed 2018 with a $235 million cash, cash
WALTHAM, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that President and Chief Executive Officer, Jesper Høiland , will present a corporate update at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 1:30 pm PST at the
Phase 3 elacestrant study has opened for enrollment Fast Track designation from the FDA for the Phase 3 study population Elacestrant pre-clinical data demonstrates further evidence of anti-tumor activity in breast cancer models with resistance to CDK 4/6 inhibitors and ESR1 mutations RAD140 Phase 1
TYMLOS® U.S. net sales continued to increase in the third quarter of 2018, totaling $27.6 million. 2019 Medicare Part D coverage for TYMLOS increased from 44% to 64% Elacestrant Phase 3 study to target a broader patient population, comprised of 2 nd and 3 rd line ER+ mBC, with potential for
WALTHAM, Mass. , Oct. 12, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 1, 2018 . The Company will host a conference call and live audio webcast at 8:00 a.m.
